Skip to main content
. 2019 Mar 19;19(5):4256–4270. doi: 10.3892/mmr.2019.10062

Figure 7.

Figure 7.

mRNA and protein expressions of SRC and CDKN2A in breast cancer tissues. (A-F) The GEPIA database, which included TCGA and GTEx RNA-sequencing data, was used to examine (A-C) SRC and (D-F) CDKN2A mRNA and protein expression in breast cancer tissues and non-cancerous breast tissues; TPM was used to calculate relative mRNA gene expression levels from 1,085 tumor and 291 non-tumor tissues, which are presented as Log2(TPM + 1) scale. (A) SRC mRNA expression levels from GEPIA. (B) Non-cancerous breast myoepithelial cells stained with CAB004023 anti-SRC antibody (not detected; brown staining was in the lumen of the ducts, not in the myoepithelial cells. (C) Breast cancer tissue stained with CAB004023 anti-SRC antibody (medium staining). (D) CDKN2A mRNA expression levels from GEPIA. (E) Non-cancerous breast myoepithelial cells stained with CAB018232 anti CDKN2A antibody (not detected). (F) Breast cancer tissue stained with CAB018232 anti CDKN2A antibody (high staining). *P<0.01. Immunohistochemistry images in B, C, E and F are presented at ×400 magnification. CDKN2A, cyclin-dependent kinase inhibitor 2A; GEPIA, Gene Expression Profiling Interactive Analysis database; GTEx, Genotype-Tissue Expression; SRC, SRC proto-oncogene non-receptor tyrosine kinase; TCGA, The Cancer Genome Atlas; TPM, transcripts per kilobase million.